Tuesday, July 02, 2024
Harvest Integrated Research Organization (HiRO) has recently acquired DeltaMed Solutions, a New Jersey-based CRO renowned for its strong presence in the US market. This strategic move, advised by Evercore, marks HiRO's third acquisition since its inception in 2020, following prior acquisitions of PharmaSols in ANZ and Courante Oncology in the US.
DeltaMed Solutions brings a team of experienced professionals specializing in data management, biostatistics, programming, RWE solutions, PK/PD analysis, regulatory affairs, and medical affairs. The company is noted for its flexible service models and exceptional track record in serving mid-sized to large pharmaceutical and biotech companies.
The integration of DeltaMed Solutions enhances HiRO's global footprint across key regions including the US, Ireland, Mainland China, Taiwan, Australia, New Zealand, Japan, South Korea, Malaysia, and the Philippines. This acquisition strengthens HiRO's capability to provide comprehensive, expedited, and customized clinical trial solutions, addressing diverse R&D needs in the pharmaceutical and biotech sectors.
Dr. Karen Chu, Founder and CEO of HiRO, expressed optimism about the acquisition, highlighting its strategic fit with HiRO's growth objectives. Dr. Chu emphasized the alignment of both companies' commitment to delivering exceptional services and advancing patient-centric research globally.
Dr. Sam Liang, President of DeltaMed Solutions, shared enthusiasm for joining HiRO, noting the opportunity to contribute their scientific expertise to the combined entity's success. Together, they aim to streamline operations and accelerate the development of innovative treatments, reinforcing their leadership in the competitive CRO industry.
This acquisition positions HiRO and DeltaMed Solutions as key players in driving healthcare and pharmaceutical advancements through their integrated, client-focused approach to clinical research.
Source: prnewswire.com
